BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

24 related articles for article (PubMed ID: 19720544)

  • 1. Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort.
    Nihtilä J; Salmenniemi U; Itälä-Remes M; Crossland RE; Gallardo D; Bogunia-Kubik K; Łacina P; Bieniaszewska M; Giebel S; Hyvärinen K; Kekäläinen E; Ritari J; Partanen J
    Hum Immunol; 2024 May; 85(3):110791. PubMed ID: 38553383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
    Karaesmen E; Rizvi AA; Preus LM; McCarthy PL; Pasquini MC; Onel K; Zhu X; Spellman S; Haiman CA; Stram DO; Pooler L; Sheng X; Zhu Q; Yan L; Liu Q; Hu Q; Webb A; Brock G; Clay-Gilmour AI; Battaglia S; Tritchler D; Liu S; Hahn T; Sucheston-Campbell LE
    Blood; 2017 Sep; 130(13):1585-1596. PubMed ID: 28811306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan.
    Ramireddy L; Chen WT; Peng CT; Hu RM; Ke TW; Chiang HC; Chang SC; Tsai FJ; Lo WY
    J Clin Lab Anal; 2015 Jul; 29(4):268-74. PubMed ID: 24840392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of MIF, CD40, and CD226 polymorphisms on risk of rheumatoid arthritis.
    Liu R; Xu N; Wang X; Shen L; Zhao G; Zhang H; Fan W
    Mol Biol Rep; 2012 Jun; 39(6):6915-22. PubMed ID: 22302395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation.
    Toubai T; Shono Y; Nishihira J; Ibata M; Suigita J; Kato N; Ohkawara T; Tone S; Lowler KP; Ota S; Tanaka J; Asaka M; Reddy P; Imamura M
    Int J Lab Hematol; 2009 Apr; 31(2):161-8. PubMed ID: 18081874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients.
    Lo JW; Leung AY; Huang XR; Lie AK; Metz C; Bucala R; Liang R; Lan HY
    Bone Marrow Transplant; 2002 Sep; 30(6):375-80. PubMed ID: 12235522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation.
    Schmidt-Hieber M; Blau IW; Richter G; Türkmen S; Bommer C; Thiel G; Neitzel H; Stroux A; Uharek L; Thiel E; Blau O
    Cancer Genet Cytogenet; 2010 Apr; 198(2):135-43. PubMed ID: 20362228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation.
    Chang YY; Greinix HT; Dickinson AM; Wolff D; Jackson GH; Andreesen R; Holler E; Hildebrandt GC
    Cytokine; 2009 Dec; 48(3):218-25. PubMed ID: 19720544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.